D-0914-2023 Class II Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0914-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Jul 10, 2023 and is designated Class II. Reason for recall: Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing The recall status is terminated (terminated Dec 18, 2023). Affected quantity: 8,880 30-count bottles.

Recall details

Product Type
Drugs
Report Date
Jul 19, 2023
Initiation Date
Jul 10, 2023
Termination Date
Dec 18, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
8,880 30-count bottles

Product description

Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical Industries. Inc. Cranbury NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India. NDC#: 62756-200-83

Reason for recall

Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing

Distribution pattern

Distributed nationwide in the USA.

Code information

Lot HAC3339A, Expires 07/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0914-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0914-2023. Report a data issue: hello@regdatalab.com.